Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes (OCT-DES)

Inclusion Criteria: * Known to have diabetes * Scheduled for percutaneous coronary intervention (PCI) with a stenosis suitable for DES implantation and OCT imaging * Reference vessel diameter over 2.5mm by operator assessment. * Able to understand and sign the written Informed Consent Form. * Able and willing to follow the Protocol requirements. Exclusion Criteria: * Inability to consent * Cardiogenic shock * Planned use of a bare metal stent * LMS coronary artery disease * Congestive cardiac failure or low ejection fraction (LVEF \<35%) * Lesions unsuitable for OCT * Total length of stented lesion greater than 55mm (total combination of stent lengths) * Age less than 18 years or age greater than 80 years * Planned surgical procedure ≤ 12 months post PCI procedure * Patient demonstrates evidence of thrombocytopenia (platelet count \< 100,000/mm3) * Patients with contraindications to ASA, clopidogrel, or prasogrel * Patient is currently on warfarin, or possibility of treatment with warfarin during the following 12 months post index procedure * Allergy to contrast * Patients enrolled in another active clinical trial. * Potential for non-compliance towards the requirements in the study protocol. * Serious known concomitant disease with a life expectancy of less than one year * Follow-up impossible (no fixed abode, etc) * Patients with renal impairment (Creatinine \>200mmol/L) * Subjects of childbearing potential